Marc Iskowitz is the Executive Editor for MM+M, a publication focused on healthcare marketing and communications. With his work featured in Campaign US and PRWeek, Marc covers a wide range of topics in the pharmaceutical industry, including drug development, healthcare policy, and marketing trends.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Marc Iskowitz focuses on the healthcare and pharmaceutical industry, with a predominant emphasis on press releases and cited data. His articles cover various aspects such as drug launches, healthcare marketing, surveys, and drug pricing.
Given his focus on press releases and cited data, Marc would likely be interested in pitches that provide access to exclusive or significant data related to the pharmaceutical industry. Additionally, he may welcome expert insights into new drug launches or trends in healthcare marketing based on credible sources within the industry.
Although Marc's geographic focus is not specified, his coverage appears to have a broader international perspective. Therefore, relevant information from any location can potentially pique his interest if it aligns with his areas of coverage within the healthcare and pharmaceutical sector.
This information evolves through artificial intelligence and human feedback. Improve this profile .
However, payers aren't likely to begin putting these GLP-1 treatments on formulary right away, drug policy experts caution.
The MM+M/Swoop 2024 Healthcare Marketers Trend Report revealed the marcoms tech stack is playing a lead role in engaging physicians, as traditional tactics make way for digital.
Language thought to be ‘predictive' applied mainly to white people on social media. Is this a red flag for AI-based analysis?
Runaway demand — and an all-out attempt to slow it down. What it was like to launch the juggernaut that ignited the obesity treatment dynamic?
Having shared full Phase 3 data for rare-disease agent olezarsen earlier this week, execs have their sights set on a 2024 filing and launch.
By: Marc Iskowitz
As AI fluency improves in pharma marketing, consultants say drugmakers can realize billions in revenue and cost savings.
Man on a mission to boost awareness of neurodegenerative disease enlists iconic buildings to glow blue.
With the multiple myeloma drug's climb from fifth- to second-line therapy, Carvykti uptake is set to expand. Legend Biotech CEO Ying Huang discusses timing of a crucial supply bump.
The announcement marks the conclusion of a process that began when Eversana acquired the Salerno-based shop last fall.
By: Marc Iskowitz
For decades April 20 has been a day to celebrate cannabis culture. But 4/20-related marketing may have become a victim of its own success.
(833) 317-6278 
